Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arch Therapeutics Inc (ARTH)

Arch Therapeutics Inc (ARTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 30,371
  • Shares Outstanding, K 186,898
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,810 K
  • 60-Month Beta 0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1210 +34.30%
on 10/28/19
0.2299 -29.32%
on 10/14/19
-0.0675 (-29.35%)
since 10/11/19
3-Month
0.1210 +34.30%
on 10/28/19
0.3100 -47.58%
on 08/14/19
-0.1185 (-42.17%)
since 08/09/19
52-Week
0.1210 +34.30%
on 10/28/19
0.6200 -73.79%
on 12/17/18
-0.2275 (-58.33%)
since 11/09/18

Most Recent Stories

More News
Arch Therapeutics Announces $2.5 Million Registered Direct Offering

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that it has entered into definitive agreements...

ARTH : 0.1625 (unch)
UPDATE - Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update today at the 2nd...

ARTH : 0.1625 (unch)
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update today at the 2nd...

ARTH : 0.1625 (unch)
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the H.C. Wainwright...

ARTH : 0.1625 (unch)
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5(TM) Topical Hemostat

Studies highlight antimicrobial activity for AC5 technology platform; AC5(TM) Topical Hemostat under Review by Notified Body

ARTH : 0.1625 (unch)
Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering

Arch Therapeutics, Inc. (OTCQB: ARTH)("Arch" or the "Company"), a developer of novel liquid, gel and solid hemostatic and wound care devices, today announced the pricing of registered direct offering of...

ARTH : 0.1625 (unch)
Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of products for dermal science and biosurgical applications, today announced that the company will attend The Symposium on Advanced...

ARTH : 0.1625 (unch)
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

ACRGF : 4.9000 (-4.48%)
ALEAF : 0.6900 (+12.20%)
ARREF : 0.3960 (-17.40%)
CWBHF : 10.6500 (-3.97%)
CORVF : 1.3800 (+2.22%)
CRLBF : 6.4200 (-1.30%)
DYAI : 5.96 (+0.68%)
ELLXF : 0.9200 (-7.54%)
EMHTF : 0.5200 (-8.95%)
GLDLF : 0.7400 (-0.88%)
GTBIF : 8.2600 (-2.82%)
GRWG : 4.6000 (-3.56%)
HEOFF : 0.7995 (+0.06%)
ITHUF : 1.4400 (-1.88%)
IMLFF : 0.2255 (-1.96%)
ISYRF : 1.1500 (unch)
MMNFF : 1.0910 (-0.82%)
MTAFF : 1.0200 (-0.97%)
MJARF : 0.4665 (+0.21%)
NUPMF : 3.2300 (-5.26%)
NLST : 0.3400 (-1.45%)
STLHF : 0.5160 (-0.77%)
TRLFF : 0.0900 (-8.35%)
AITB : 5.24 (+2.34%)
ALYE : 1.3500 (unch)
ARTH : 0.1625 (unch)
ARHH : 1.4755 (+11.78%)
ATEA : 11.5500 (+0.09%)
BICXD : 4.5400 (-9.02%)
BRTI : 0.1395 (+8.14%)
CNBX : 0.1348 (-5.73%)
CLOK : 0.6500 (-8.45%)
CVSI : 1.7050 (-0.29%)
DUOT : 0.4800 (+5.52%)
EVLLF : 1.1000 (+3.77%)
FLUX : 8.0000 (-13.04%)
GBPT : 7.0000 (-12.50%)
GTBP : 0.1635 (+9.00%)
KSHB : 1.7800 (-2.73%)
MRMD : 0.8740 (+2.84%)
MLCPF : 3.5200 (+11.47%)
MRIC : 4.02 (+3.88%)
NMUS : 0.6500 (-9.52%)
NWGI : 0.3500 (+2.94%)
OWCP : 0.0073 (-5.19%)
PPCB : 0.3700 (-11.90%)
QBIO : 0.3950 (+6.76%)
RSSS : 3.2000 (+2.24%)
VTLR : 0.0650 (+8.33%)
WIZD : 0.0800 (-3.03%)
OTCM : 34.1000 (+0.29%)
Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference

Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 31 Annual ROTH...

ARTH : 0.1625 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARTH with:

Key Turning Points

2nd Resistance Point 0.1702
1st Resistance Point 0.1663
Last Price 0.1625
1st Support Level 0.1548
2nd Support Level 0.1472

See More

52-Week High 0.6200
Fibonacci 61.8% 0.4294
Fibonacci 50% 0.3705
Fibonacci 38.2% 0.3116
Last Price 0.1625
52-Week Low 0.1210

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar